MYC in Germinal Center‐derived lymphomas: Mechanisms and therapeutic opportunities

Genetics of diffuse large B-cell lymphoma

(2018) Laura Pasqualucci et al.   BLOOD

Critical influences on the pathogenesis of follicular lymphoma

(2018) Ralf Küppers et al.   BLOOD

High-grade B-cell lymphoma withMYCandBCL2and/orBCL6rearrangements with diffuse large B-cell lymphoma morphology

(2018) David W. Scott et al.   BLOOD

Anti‐tumor efficacy of a novel CLK inhibitor via targeting RNA splicing and MYC‐dependent vulnerability

(2018) Kenichi Iwai et al.   EMBO Molecular Medicine

B Cell Receptor and CD40 Signaling Are Rewired for Synergistic Induction of the c-Myc Transcription Factor in Germinal Center B Cells

(2018) Wei Luo et al.   IMMUNITY

Tip60: updates

(2018) Ahmed H. Ghobashi et al.   JOURNAL OF APPLIED GENETICS

Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial

(2018) Philippe Armand et al.   JOURNAL OF CLINICAL ONCOLOGY

ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial

(2018) John M Wrangle et al.   LANCET ONCOLOGY

Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial

(2018) Andrew X Zhu et al.   LANCET ONCOLOGY

Enhancer invasion shapes MYCN-dependent transcriptional amplification in neuroblastoma

(2018) Rhamy Zeid et al.   NATURE GENETICS

The RNA-binding protein PTBP1 is necessary for B cell selection in germinal centers

(2018) Elisa Monzón-Casanova et al.   NATURE IMMUNOLOGY

DNA repair processes are critical mediators of p53-dependent tumor suppression

(2018) Ana Janic et al.   NATURE MEDICINE

Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes

(2018) Bjoern Chapuy et al.   NATURE MEDICINE

Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma

(2018) Roland Schmitz et al.   NEW ENGLAND JOURNAL OF MEDICINE

SLAM-seq defines direct gene-regulatory functions of the BRD4-MYC axis

(2018) Matthias Muhar et al.   SCIENCE

BRD4 and MYC—clarifying regulatory specificity

(2018) Arianna Sabò et al.   SCIENCE

Therapeutic synergy between tigecycline and venetoclax in a preclinical model of MYC / BCL2 double-hit B cell lymphoma

(2018) Micol Ravà et al.   Science Translational Medicine

CREBBP/EP300 bromodomains are critical to sustain the GATA1/MYC regulatory axis in proliferation

(2018) Veronica Garcia-Carpizo et al.   Epigenetics & Chromatin

Hijacking a key chromatin modulator creates epigenetic vulnerability for MYC-driven cancer

(2018) Zhenhua Yang et al.   JOURNAL OF CLINICAL INVESTIGATION

Human germinal center transcriptional programs are de-synchronized in B cell lymphoma

(2018) Pierre Milpied et al.   NATURE IMMUNOLOGY

Transcriptional addiction in cancer cells is mediated by YAP/TAZ through BRD4

(2018) Francesca Zanconato et al.   NATURE MEDICINE

The Senescence–Stemness Alliance – A Cancer-Hijacked Regeneration Principle

(2018) Maja Milanovic et al.   TRENDS IN CELL BIOLOGY

Targeting Processive Transcription Elongation via SEC Disruption for MYC-Induced Cancer Therapy

(2018) Kaiwei Liang et al.   CELL

PLK1 stabilizes a MYC-dependent kinase network in aggressive B cell lymphomas

(2018) Yuan Ren et al.   JOURNAL OF CLINICAL INVESTIGATION

A comprehensive review on Aurora kinase: Small molecule inhibitors and clinical trial studies

(2017) Ankit C. Borisa et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Integrative analysis of RNA polymerase II and transcriptional dynamics upon MYC activation

(2017) Stefano de Pretis et al.   GENOME RESEARCH

Germinal Center Selection and Affinity Maturation Require Dynamic Regulation of mTORC1 Kinase

(2017) Jonatan Ersching et al.   IMMUNITY

TP53 mutation and survival in aggressive B cell lymphoma

(2017) Thorsten Zenz et al.   INTERNATIONAL JOURNAL OF CANCER

Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

(2017) Matthew S. Davids et al.   JOURNAL OF CLINICAL ONCOLOGY

Genetic landscape and deregulated pathways in B-cell lymphoid malignancies

(2017) R. Rosenquist et al.   JOURNAL OF INTERNAL MEDICINE

Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial

(2017) Yoon-Koo Kang et al.   LANCET

Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial

(2017) Anthony B El-Khoueiry et al.   LANCET

Identification of potential ibrutinib combinations in hematological malignancies using a combination high-throughput screen

(2017) Michael Schaffer et al.   LEUKEMIA & LYMPHOMA

IGH/MYC Translocation Associates with BRCA2 Deficiency and Synthetic Lethality to PARP1 Inhibitors

(2017) Silvia Maifrede et al.   MOLECULAR CANCER RESEARCH

Combination of Ibrutinib and ABT-199 in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma

(2017) Hsu-Ping Kuo et al.   MOLECULAR CANCER THERAPEUTICS

Global Inhibition with Specific Activation: How p53 and MYC Redistribute the Transcriptome in the DNA Double-Strand Break Response

(2017) Joshua R. Porter et al.   MOLECULAR CELL

NRF2 Is a Major Target of ARF in p53-Independent Tumor Suppression

(2017) Delin Chen et al.   MOLECULAR CELL

Myc Regulates Chromatin Decompaction and Nuclear Architecture during B Cell Activation

(2017) Kyong-Rim Kieffer-Kwon et al.   MOLECULAR CELL

The B-cell receptor controls fitness of MYC-driven lymphoma cells via GSK3β inhibition

(2017) Gabriele Varano et al.   NATURE

Senescence-associated reprogramming promotes cancer stemness

(2017) Maja Milanovic et al.   NATURE

Purine synthesis promotes maintenance of brain tumor initiating cells in glioma

(2017) Xiuxing Wang et al.   NATURE NEUROSCIENCE

BET-Bromodomain Inhibitors Engage the Host Immune System and Regulate Expression of the Immune Checkpoint Ligand PD-L1

(2017) Simon J. Hogg et al.   Cell Reports

MYC—Master Regulator of the Cancer Epigenome and Transcriptome

(2017) Candace J. Poole et al.   Genes

Targeting MYC in cancer therapy: RNA processing offers new opportunities

(2016) Cheryl M. Koh et al.   BIOESSAYS

Impact of dual expression of MYC and BCL2 by immunohistochemistry on the risk of CNS relapse in DLBCL

(2016) K. J. Savage et al.   BLOOD

Approach to the diagnosis and treatment of high-grade B-cell lymphomas withMYCandBCL2and/orBCL6rearrangements

(2016) Pierre Sesques et al.   BLOOD

The 2016 revision of the World Health Organization classification of lymphoid neoplasms

(2016) S. H. Swerdlow et al.   BLOOD

MYCN controls an alternative RNA splicing program in high-risk metastatic neuroblastoma

(2016) Shile Zhang et al.   CANCER LETTERS

Cancer Differentiating Agent Hexamethylene Bisacetamide Inhibits BET Bromodomain Proteins

(2016) Lisa M. Nilsson et al.   CANCER RESEARCH

Identification of MYC-Dependent Transcriptional Programs in Oncogene-Addicted Liver Tumors

(2016) T. R. Kress et al.   CANCER RESEARCH

The Emerging Hallmarks of Cancer Metabolism

(2016) Natalya N. Pavlova et al.   Cell Metabolism

The Transcription Factor AP4 Mediates Resolution of Chronic Viral Infection through Amplification of Germinal Center B Cell Responses

(2016) Chun Chou et al.   IMMUNITY

Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study

(2016) Alexander M. Lesokhin et al.   JOURNAL OF CLINICAL ONCOLOGY

Molecular functions of the transcription factors E2A and E2-2 in controlling germinal center B cell and plasma cell development

(2016) Miriam Wöhner et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Cyclin Dependent Kinase 9 Inhibitors for Cancer Therapy

(2016) Yogesh A. Sonawane et al.   JOURNAL OF MEDICINAL CHEMISTRY

Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial

(2016) Sarah B Goldberg et al.   LANCET ONCOLOGY

Compensatory RNA polymerase 2 loading determines the efficacy and transcriptional selectivity of JQ1 in Myc-driven tumors

(2016) E Donato et al.   LEUKEMIA

Id3 Orchestrates Germinal Center B Cell Development

(2016) Shuwen Chen et al.   MOLECULAR AND CELLULAR BIOLOGY

CD20-Targeting Immunotherapy Promotes Cellular Senescence in B-Cell Lymphoma

(2016) J. H. M. Da britz et al.   MOLECULAR CANCER THERAPEUTICS

BET Inhibition Induces Apoptosis in Aggressive B-Cell Lymphoma via Epigenetic Regulation of BCL-2 Family Members

(2016) S. J. Hogg et al.   MOLECULAR CANCER THERAPEUTICS

Polo-like Kinase-1 Regulates Myc Stabilization and Activates a Feedforward Circuit Promoting Tumor Cell Survival

(2016) Daibiao Xiao et al.   MOLECULAR CELL

Metabolic maintenance of cell asymmetry following division in activated T lymphocytes

(2016) Katherine C. Verbist et al.   NATURE

A MYC–aurora kinase A protein complex represents an actionable drug target in p53-altered liver cancer

(2016) Daniel Dauch et al.   NATURE MEDICINE

The landscape of new drugs in lymphoma

(2016) Anas Younes et al.   Nature Reviews Clinical Oncology

BET bromodomain inhibitors synergize with ATR inhibitors to induce DNA damage, apoptosis, senescence-associated secretory pathway and ER stress in Myc-induced lymphoma cells

(2016) S V Muralidharan et al.   ONCOGENE

MYC regulates the antitumor immune response through CD47 and PD-L1

(2016) S. C. Casey et al.   SCIENCE

BET inhibitors in the treatment of hematologic malignancies: current insights and future prospects

(2016) Hidayatullah Munshi et al.   OncoTargets and Therapy

Critical B-lymphoid cell intrinsic role of endogenous MCL-1 in c-MYC-induced lymphomagenesis

(2016) S Grabow et al.   Cell Death & Disease

Double hit lymphoma: from biology to therapeutic implications

(2016) Mauricio Burotto et al.   Expert Review of Hematology

BPTF is required for c-MYC transcriptional activity and in vivo tumorigenesis

(2016) Laia Richart et al.   Nature Communications

Loss of a Single Mcl-1 Allele Inhibits MYC-Driven Lymphomagenesis by Sensitizing Pro-B Cells to Apoptosis

(2016) Stephanie Grabow et al.   Cell Reports

Critical roles of mTOR Complex 1 and 2 for T follicular helper cell differentiation and germinal center responses

(2016) Jialong Yang et al.   eLife

Different promoter affinities account for specificity in MYC-dependent gene regulation

(2016) Francesca Lorenzin et al.   eLife

The SMAC mimetic, LCL-161, reduces survival in aggressive MYC-driven lymphoma while promoting susceptibility to endotoxic shock

(2016) A C West et al.   Oncogenesis

Fundamentals of cancer metabolism

(2016) R. J. DeBerardinis et al.   Science Advances

Expression Profiles of MYC Protein and MYC Gene Rearrangement in Lymphomas

(2015) Karen M. Chisholm et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

Synthetic Lethality and Cancer Therapy: Lessons Learned from the Development of PARP Inhibitors

(2015) Christopher J. Lord et al.   Annual Review of Medicine

Myc induced replicative stress response: How to cope with it and exploit it

(2015) Sara Rohban et al.   Biochimica et Biophysica Acta-Gene Regulatory Mechanisms

Small-molecule inhibitors of the Myc oncoprotein

(2015) Steven Fletcher et al.   Biochimica et Biophysica Acta-Gene Regulatory Mechanisms

Functional-genetic dissection of HDAC dependencies in mouse lymphoid and myeloid malignancies

(2015) G. M. Matthews et al.   BLOOD

Targeting glutaminolysis has antileukemic activity in acute myeloid leukemia and synergizes with BCL-2 inhibition

(2015) N. Jacque et al.   BLOOD

WDR5 Supports an N-Myc Transcriptional Complex That Drives a Protumorigenic Gene Expression Signature in Neuroblastoma

(2015) Y. Sun et al.   CANCER RESEARCH

The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs

(2015) M. Boi et al.   CLINICAL CANCER RESEARCH

MYC as Therapeutic Target for Embryonal Tumors: Potential and Challenges

(2015) Tarek Shalaby et al.   CURRENT CANCER DRUG TARGETS

MYC-Mediated Synthetic Lethality for Treating Tumors

(2015) Xin Li et al.   CURRENT CANCER DRUG TARGETS

Double-hit and double-protein-expression lymphomas: aggressive and refractory lymphomas

(2015) Clémentine Sarkozy et al.   LANCET ONCOLOGY

The diagnostic gray zone between Burkitt lymphoma and diffuse large B-cell lymphoma is also a gray zone of the mutational spectrum

(2015) S Momose et al.   LEUKEMIA

Concurrent inhibition of MYC and BCL2 is a potentially effective treatment strategy for double hit and triple hit B-cell lymphomas

(2015) Munevver Cinar et al.   LEUKEMIA RESEARCH

Interaction with WDR5 Promotes Target Gene Recognition and Tumorigenesis by MYC

(2015) Lance R. Thomas et al.   MOLECULAR CELL

Mutations driving CLL and their evolution in progression and relapse

(2015) Dan A. Landau et al.   NATURE

The spliceosome is a therapeutic vulnerability in MYC-driven cancer

(2015) Tiffany Y.-T. Hsu et al.   NATURE

Ferroptosis as a p53-mediated activity during tumour suppression

(2015) Le Jiang et al.   NATURE

MYC regulates the core pre-mRNA splicing machinery as an essential step in lymphomagenesis

(2015) Cheryl M. Koh et al.   NATURE

The histone lysine methyltransferase KMT2D sustains a gene expression program that represses B cell lymphoma development

(2015) Ana Ortega-Molina et al.   NATURE MEDICINE

PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma

(2015) Stephen M. Ansell et al.   NEW ENGLAND JOURNAL OF MEDICINE

Oncogenic c-Myc-induced lymphomagenesis is inhibited non-redundantly by the p19Arf–Mdm2–p53 and RP–Mdm2–p53 pathways

(2015) X Meng et al.   ONCOGENE

Combined loss of PUMA and p21 accelerates c-MYC-driven lymphoma development considerably less than loss of one allele of p53

(2015) L J Valente et al.   ONCOGENE

MYC oncogene overexpression drives renal cell carcinoma in a mouse model through glutamine metabolism

(2015) Emelyn H. Shroff et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

MYC and metabolism on the path to cancer

(2015) Annie L. Hsieh et al.   SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY

MYC Alterations in Diffuse Large B-Cell Lymphomas

(2015) Kennosuke Karube et al.   SEMINARS IN HEMATOLOGY

MYC, Metabolism, and Cancer

(2015) Z. E. Stine et al.   Cancer Discovery

Combination Therapy Targeting Ribosome Biogenesis and mRNA Translation Synergistically Extends Survival in MYC-Driven Lymphoma

(2015) J. R. Devlin et al.   Cancer Discovery

CDK9 inhibition by dinaciclib potently suppresses Mcl-1 to induce durable apoptotic responses in aggressive MYC-driven B-cell lymphoma in vivo

(2015) G P Gregory et al.   LEUKEMIA

Aberrations of MYC Are a Common Event in B-Cell Prolymphocytic Leukemia

(2014) Ellen Flatley et al.   AMERICAN JOURNAL OF CLINICAL PATHOLOGY

B-cell prolymphocytic leukemia: a specific subgroup of mantle cell lymphoma

(2014) V. H. J. van der Velden et al.   BLOOD

Myc-induced SUMOylation is a therapeutic vulnerability for B-cell lymphoma

(2014) A. Hoellein et al.   BLOOD

Combination of ibrutinib with ABT-199: synergistic effects on proliferation inhibition and apoptosis in mantle cell lymphoma cells through perturbation of BTK, AKT and BCL2 pathways

(2014) Xiaoxian Zhao et al.   BRITISH JOURNAL OF HAEMATOLOGY

Drugging MYCN through an Allosteric Transition in Aurora Kinase A

(2014) William Clay Gustafson et al.   CANCER CELL

Targeting Transcriptional Addictions in Small Cell Lung Cancer with a Covalent CDK7 Inhibitor

(2014) Camilla L. Christensen et al.   CANCER CELL

CDK7 Inhibition Suppresses Super-Enhancer-Linked Oncogenic Transcription in MYCN-Driven Cancer

(2014) Edmond Chipumuro et al.   CELL

CDK9-mediated transcription elongation is required for MYC addiction in hepatocellular carcinoma

(2014) Chun-Hao Huang et al.   GENES & DEVELOPMENT

Inactivation of MYC reverses tumorigenesis

(2014) Y. Li et al.   JOURNAL OF INTERNAL MEDICINE

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial

(2014) Caroline Robert et al.   LANCET

Targeting transcription regulation in cancer with a covalent CDK7 inhibitor

(2014) Nicholas Kwiatkowski et al.   NATURE

Clonal selection in the germinal centre by regulated proliferation and hypermutation

(2014) Alexander D. Gitlin et al.   NATURE

Selective transcriptional regulation by Myc in cellular growth control and lymphomagenesis

(2014) Arianna Sabò et al.   NATURE

Activation and repression by oncogenic MYC shape tumour-specific gene expression profiles

(2014) Susanne Walz et al.   NATURE

c-Myc-induced transcription factor AP4 is required for host protection mediated by CD8+ T cells

(2014) Chun Chou et al.   NATURE IMMUNOLOGY

Precision therapy for lymphoma—current state and future directions

(2014) Andrew M. Intlekofer et al.   Nature Reviews Clinical Oncology

Targeting RNA polymerase I to treat MYC-driven cancer

(2014) G Poortinga et al.   ONCOGENE

Alisertib Added to Rituximab and Vincristine Is Synthetic Lethal and Potentially Curative in Mice with Aggressive DLBCL Co-Overexpressing MYC and BCL2

(2014) Daruka Mahadevan et al.   PLoS One

BET and HDAC inhibitors induce similar genes and biological effects and synergize to kill in Myc-induced murine lymphoma

(2014) Joydeep Bhadury et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Linking Tumor Mutations to Drug Responses via a Quantitative Chemical–Genetic Interaction Map

(2014) Maria M. Martins et al.   Cancer Discovery

Genetics of Follicular Lymphoma Transformation

(2014) Laura Pasqualucci et al.   Cell Reports

Synthetic Lethal Screens as a Means to Understand and Treat MYC-Driven Cancers

(2014) S. Cermelli et al.   Cold Spring Harbor Perspectives in Medicine

Therapeutic Strategies to Inhibit MYC

(2014) M. R. McKeown et al.   Cold Spring Harbor Perspectives in Medicine

Genome Recognition by MYC

(2014) A. Sabo et al.   Cold Spring Harbor Perspectives in Medicine

MYC Activation Is a Hallmark of Cancer Initiation and Maintenance

(2014) M. Gabay et al.   Cold Spring Harbor Perspectives in Medicine

Oncogene withdrawal engages the immune system to induce sustained cancer regression

(2014) Stephanie C Casey et al.   Journal for ImmunoTherapy of Cancer

Combined inhibition of PI3K-related DNA damage response kinases and mTORC1 induces apoptosis in MYC-driven B-cell lymphomas

(2013) J. Shortt et al.   BLOOD

Genome-wide copy-number analyses reveal genomic abnormalities involved in transformation of follicular lymphoma

(2013) A. Bouska et al.   BLOOD

MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program

(2013) S. Hu et al.   BLOOD

Small Molecule Inhibitors of Aurora-A Induce Proteasomal Degradation of N-Myc in Childhood Neuroblastoma

(2013) Markus Brockmann et al.   CANCER CELL

Discovery and Characterization of Super-Enhancer-Associated Dependencies in Diffuse Large B Cell Lymphoma

(2013) Bjoern Chapuy et al.   CANCER CELL

Blocking Lactate Export by Inhibiting the Myc Target MCT1 Disables Glycolysis and Glutathione Synthesis

(2013) J. R. Doherty et al.   CANCER RESEARCH

AKT signalling is required for ribosomal RNA synthesis and progression of Eμ-MycB-cell lymphomain vivo

(2013) Jennifer R. Devlin et al.   FEBS Journal

Biological characterization of adult MYC-translocation-positive mature B-cell lymphomas other than molecular Burkitt lymphoma

(2013) S. M. Aukema et al.   HAEMATOLOGICA

MYC protein expression and genetic alterations have prognostic impact in patients with diffuse large B-cell lymphoma treated with immunochemotherapy

(2013) A. Valera et al.   HAEMATOLOGICA

Transcriptional Regulation of Germinal Center B and Plasma Cell Fates by Dynamical Control of IRF4

(2013) Kyoko Ochiai et al.   IMMUNITY

ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

(2013) Andrew J Souers et al.   NATURE MEDICINE

Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy

(2013) Peter E. Czabotar et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

(2013) Omid Hamid et al.   NEW ENGLAND JOURNAL OF MEDICINE

Myc and mTOR converge on a common node in protein synthesis control that confers synthetic lethality in Myc-driven cancers

(2013) M. Pourdehnad et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Preclinical screening of histone deacetylase inhibitors combined with ABT-737, rhTRAIL/MD5-1 or 5-azacytidine using syngeneic Vk*MYC multiple myeloma

(2013) G M Matthews et al.   Cell Death & Disease

Targeting MYCN in Neuroblastoma by BET Bromodomain Inhibition

(2013) Alexandre Puissant et al.   Cancer Discovery

Germinal Centers

(2012) Gabriel D. Victora et al.   Annual Review of Immunology

Targeted genomic sequencing of pediatric Burkitt lymphoma identifies recurrent alterations in antiapoptotic and chromatin-remodeling genes

(2012) L. Giulino-Roth et al.   BLOOD

Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy

(2012) M. Chesi et al.   BLOOD

E6AP ubiquitin ligase regulates PML-induced senescence in Myc-driven lymphomagenesis

(2012) K. Wolyniec et al.   BLOOD

Identification of human germinal center light and dark zone cells and their relationship to human B-cell lymphomas

(2012) G. D. Victora et al.   BLOOD

BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia

(2012) C. J. Ott et al.   BLOOD

Synergy between PI3K Signaling and MYC in Burkitt Lymphomagenesis

(2012) Sandrine Sander et al.   CANCER CELL

Inhibition of RNA Polymerase I as a Therapeutic Strategy to Promote Cancer-Specific Activation of p53

(2012) Megan J. Bywater et al.   CANCER CELL

Tristetraprolin Impairs Myc-Induced Lymphoma and Abolishes the Malignant State

(2012) Robert J. Rounbehler et al.   CELL

c-Myc Is a Universal Amplifier of Expressed Genes in Lymphocytes and Embryonic Stem Cells

(2012) Zuqin Nie et al.   CELL

Transcriptional Amplification in Tumor Cells with Elevated c-Myc

(2012) Charles Y. Lin et al.   CELL

MYC on the Path to Cancer

(2012) Chi V. Dang   CELL

Aurora A Inhibitor (MLN8237) plus Vincristine plus Rituximab Is Synthetic Lethal and a Potential Curative Therapy in Aggressive B-cell Non-Hodgkin Lymphoma

(2012) D. Mahadevan et al.   CLINICAL CANCER RESEARCH

Roles of BCL6 in normal and transformed germinal center B cells

(2012) Katia Basso et al.   IMMUNOLOGICAL REVIEWS

Pathogenesis of follicular lymphoma

(2012) Robert Kridel et al.   JOURNAL OF CLINICAL INVESTIGATION

Concurrent Expression of MYC and BCL2 in Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone

(2012) Nathalie A. Johnson et al.   JOURNAL OF CLINICAL ONCOLOGY

Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics

(2012) Roland Schmitz et al.   NATURE

Deregulated MYC expression induces dependence upon AMPK-related kinase 5

(2012) Lidan Liu et al.   NATURE

The genetic landscape of mutations in Burkitt lymphoma

(2012) Cassandra Love et al.   NATURE GENETICS

Recurrent mutation of the ID3 gene in Burkitt lymphoma identified by integrated genome, exome and transcriptome sequencing

(2012)   NATURE GENETICS

The proto-oncogene MYC is required for selection in the germinal center and cyclic reentry

(2012) David Dominguez-Sola et al.   NATURE IMMUNOLOGY

The cell-cycle regulator c-Myc is essential for the formation and maintenance of germinal centers

(2012) Dinis Pedro Calado et al.   NATURE IMMUNOLOGY

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

(2012) Julie R. Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Rapid generation of human B-cell lymphomas via combined expression of Myc and Bcl2 and their use as a preclinical model for biological therapies

(2012) I Leskov et al.   ONCOGENE

Functional genomics identifies therapeutic targets for MYC-driven cancer

(2012) M. Toyoshima et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Two sides of the Myc-induced DNA damage response: from tumor suppression to tumor maintenance

(2012) Stefano Campaner et al.   Cell Division

The mTORC1 Inhibitor Everolimus Prevents and Treats Eμ- Myc Lymphoma by Restoring Oncogene-Induced Senescence

(2012) Meaghan Wall et al.   Cancer Discovery

Mouse Genetics Suggests Cell-Context Dependency for Myc-Regulated Metabolic Enzymes during Tumorigenesis

(2012) Lisa M. Nilsson et al.   PLoS Genetics

Aerobic Glycolysis: Meeting the Metabolic Requirements of Cell Proliferation

(2011) Sophia Y. Lunt et al.   Annual Review of Cell and Developmental Biology

The cooperating mutation or "second hit" determines the immunologic visibility toward MYC-induced murine lymphomas

(2011) C. Schuster et al.   BLOOD

The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications

(2011) E. Campo et al.   BLOOD

The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation

(2011) D. Rossi et al.   BLOOD

BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc

(2011) Jake E. Delmore et al.   CELL

Tip60: Connecting chromatin to DNA damage signaling

(2011) Yingli Sun et al.   CELL CYCLE

Chk2 deficiency in Myc overexpressing lymphoma cells elicits a synergistic lethal response in combination with PARP inhibition

(2011) Andreas Höglund et al.   CELL CYCLE

Therapeutic Implications for the Induced Levels of Chk1 in Myc-Expressing Cancer Cells

(2011) A. Hoglund et al.   CLINICAL CANCER RESEARCH

Endogenous Myc maintains the tumor microenvironment

(2011) N. M. Sodir et al.   GENES & DEVELOPMENT

Transformation of Indolent B-Cell Lymphomas

(2011) Silvia Montoto et al.   JOURNAL OF CLINICAL ONCOLOGY

B Lymphocyte Commitment Program Is Driven by the Proto-Oncogene c-myc

(2011) M. Vallespinos et al.   JOURNAL OF IMMUNOLOGY

RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia

(2011) Johannes Zuber et al.   NATURE

Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia

(2011) Mark A. Dawson et al.   NATURE

Analysis of the coding genome of diffuse large B-cell lymphoma

(2011) Laura Pasqualucci et al.   NATURE GENETICS

Adaptive clinical trials in oncology

(2011) Donald A. Berry   Nature Reviews Clinical Oncology

Exploiting oncogene-induced replicative stress for the selective killing of Myc-driven tumors

(2011) Matilde Murga et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

Efficacy of CHK inhibitors as single agents in MYC-driven lymphoma cells

(2011) P T Ferrao et al.   ONCOGENE

Genome-wide mapping of Myc binding and gene regulation in serum-stimulated fibroblasts

(2011) D Perna et al.   ONCOGENE

Targeting MYC dependence in cancer by inhibiting BET bromodomains

(2011) J. A. Mertz et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

A SUMOylation-Dependent Transcriptional Subprogram Is Required for Myc-Driven Tumorigenesis

(2011) J. D. Kessler et al.   SCIENCE

Aurora kinases A and B are up-regulated by Myc and are essential for maintenance of the malignant state

(2010) J. den Hollander et al.   BLOOD

Tumor Stroma-Derived TGF-β Limits Myc-Driven Lymphomagenesis via Suv39h1-Dependent Senescence

(2010) Maurice Reimann et al.   CANCER CELL

An ARF-Independent c-MYC-Activated Tumor Suppression Pathway Mediated by Ribosomal Protein-Mdm2 Interaction

(2010) Everardo Macias et al.   CANCER CELL

CD4+ T Cells Contribute to the Remodeling of the Microenvironment Required for Sustained Tumor Regression upon Oncogene Inactivation

(2010) Kavya Rakhra et al.   CANCER CELL

Chemoprevention of B-Cell Lymphomas by Inhibition of the Myc Target Spermidine Synthase

(2010) T. P. Forshell et al.   Cancer Prevention Research

Origin of Chromosomal Translocations in Lymphoid Cancer

(2010) André Nussenzweig et al.   CELL

c-Myc Regulates Transcriptional Pause Release

(2010) Peter B. Rahl et al.   CELL

Germinal Center Dynamics Revealed by Multiphoton Microscopy with a Photoactivatable Fluorescent Reporter

(2010) Gabriel D. Victora et al.   CELL

The interaction between Myc and Miz1 is required to antagonize TGF -dependent autocrine signaling during lymphoma formation and maintenance

(2010) J. van Riggelen et al.   GENES & DEVELOPMENT

Rearrangement ofMYCIs Associated With Poor Prognosis in Patients With Diffuse Large B-Cell Lymphoma Treated in the Era of Rituximab

(2010) Sharon Barrans et al.   JOURNAL OF CLINICAL ONCOLOGY

The landscape of somatic copy-number alteration across human cancers

(2010) Rameen Beroukhim et al.   NATURE

Deep-sequencing identification of the genomic targets of the cytidine deaminase AID and its cofactor RPA in B lymphocytes

(2010) Arito Yamane et al.   NATURE IMMUNOLOGY

Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression

(2010) A. Le et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Glutamine addiction: a new therapeutic target in cancer

(2010) David R. Wise et al.   TRENDS IN BIOCHEMICAL SCIENCES

Myc sensitizes p53-deficient cancer cells to the DNA-damaging effects of the DNA methyltransferase inhibitor decitabine

(2009) A. Hoglund et al.   BLOOD

The histone deacetylase inhibitors LAQ824 and LBH589 do not require death receptor signaling or a functional apoptosome to mediate tumor cell death or therapeutic efficacy

(2009) L. Ellis et al.   BLOOD

Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival

(2009) N. A. Johnson et al.   BLOOD

MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy

(2009) K. J. Savage et al.   BLOOD

PI3 Kinase Signals BCR-Dependent Mature B Cell Survival

(2009) Lakshmi Srinivasan et al.   CELL

Puma and to a lesser extent Noxa are suppressors of Myc-induced lymphomagenesis

(2009) E M Michalak et al.   CELL DEATH AND DIFFERENTIATION

CXCR4 Expression Functionally Discriminates Centroblasts versus Centrocytes within Human Germinal Center B Cells

(2009) G. Caron et al.   JOURNAL OF IMMUNOLOGY

c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism

(2009) Ping Gao et al.   NATURE

Cdk2 suppresses cellular senescence induced by the c-myc oncogene

(2009) Stefano Campaner et al.   NATURE CELL BIOLOGY

Phosphorylation by Cdk2 is required for Myc to repress Ras-induced senescence in cotransformation

(2009) P. Hydbring et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

BCL6 suppression of BCL2 via Miz1 and its disruption in diffuse large B cell lymphoma

(2009) M. Saito et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Regulation and Functions of Blimp-1 in T and B Lymphocytes

(2008) Gislâine Martins et al.   Annual Review of Immunology

Defining the target specificity of ABT-737 and synergistic antitumor activities in combination with histone deacetylase inhibitors

(2008) K. F. Whitecross et al.   BLOOD

Molecular profiling of pediatric mature B-cell lymphoma treated in population-based prospective clinical trials

(2008) W. Klapper et al.   BLOOD

MYC translocation in chronic lymphocytic leukaemia is associated with increased prolymphocytes and a poor prognosis

(2008) Yang O. Huh et al.   BRITISH JOURNAL OF HAEMATOLOGY

C-Myc Is a Critical Mediator of the Phenotypes of Apc Loss in the Intestine

(2008) J. A. Wilkins et al.   CANCER RESEARCH

Dynamic regulation ofc-Myc proto-oncogene expression during lymphocyte development revealed by aGFP-c-Myc knock-in mouse

(2008) Ching-Yu Huang et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Myc's broad reach

(2008) M. Eilers et al.   GENES & DEVELOPMENT

Population-Based Analysis of Incidence and Outcome of Transformed Non-Hodgkin's Lymphoma

(2008) Abdulwahab J. Al-Tourah et al.   JOURNAL OF CLINICAL ONCOLOGY

Selection against PUMA Gene Expression in Myc-Driven B-Cell Lymphomagenesis

(2008) S. P. Garrison et al.   MOLECULAR AND CELLULAR BIOLOGY

Modelling Myc inhibition as a cancer therapy

(2008) Laura Soucek et al.   NATURE

Suppression of Myc oncogenic activity by ribosomal protein haploinsufficiency

(2008) Maria Barna et al.   NATURE